News | Congenital Heart | October 19, 2016

St. Jude Medical Announces New Clinical Trial to Treat Congenital Heart Defects

St. Jude working with FDA and top pediatric cardiology experts, is helping physicians evaluate Amplatzer Duct Occluder II AS as alternative to open heart surgery for babies, including premature newborns

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS

October 19, 2016 — St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric clinical trial. The U.S. IDE clinical trial will evaluate the safety and effectiveness of the St. Jude Medical Amplatzer Duct Occluder II AS (ADO II AS), a first-of-its-kind device specifically designed for closure of the small patent ductus arteriosus (PDA).

St. Jude Medical now has two ongoing U.S. cardiology IDE clinical trials for pediatric patients. In 2014, the company launched the HALO trial to evaluate the safety and effectiveness of the SJM Masters HP Series 15mm mechanical heart valve, what the company calls the smallest pediatric mechanical heart valve in the world.

Congenital heart disease (CHD) is the most common cause of major congenital anomalies, representing a major global health challenge. Every year CHD affects 1.35 million babies worldwide. Nearly 25 percent of babies with a congenital heart defect require surgery during their first year.

“The patients who would be eligible for this study are the tiniest and most fragile we care for — severely premature newborns who in many cases are critically ill from the presence of a patent ductus arteriosus (PDA),” said national investigator Evan Zahn, M.D., director of the Guerin Family Congenital Heart Program in the Cedars-Sinai Heart Institute and Department of Pediatrics at Cedars‐Sinai Medical Center in Los Angeles. “The Amplatzer Duct Occluder II AS will provide an experimental option to surgery. Surgery has many risks in this delicate population and a minimally invasive approach is desperately needed for this fairly common and often quite serious problem.”

Despite the large number of babies worldwide born with CHD, many children are treated with adult-sized devices, which may not be optimal for their tiny hearts. St. Jude Medical and the U.S. Food & Drug Administration (FDA) have long recognized the need for solutions and educational resources to support pediatric patients.

In 2007, the U.S. Congress passed the Pediatric Medical Device Safety and Improvement Act to prompt development of medical devices designed and engineered specifically for the pediatric patient population. In collaboration with the FDA and top congenital heart disease experts, St. Jude Medical is addressing the unique challenges of developing, evaluating and bringing to market devices intended for pediatric use.

The ADO II AS IDE trial will enroll a maximum of 50 patients at up to 10 sites nationwide. Patients in the trial will fall within two study groups:

  • A minimum of 15 patients less than or equal to 2 kg (approx. 4.4 pounds); and
  • A minimum of 25 patients greater than 2 kg.

Designed to treat PDA — one of the most common of all congenital heart anomalies — the ADO II AS device conforms to the smallest ducts while achieving complete closure from a pulmonary or aortic artery approach.

Data collected during the ADO II AS trial across all trial sites will be used to support a pre-market approval submission of the device to FDA. The ADO II AS device is currently approved for use in more than 50 countries outside the United States.

The other pediatric clinical trial from St. Jude Medical is evaluating the safety and efficacy of the SJM Masters HP Series 15mm mechanical heart valve. In the United States alone, more than 35,000 babies are born each year with congenital heart defects, some of which will impact valve function to the point they cannot be repaired and will require surgical valve replacement. The HALO IDE trial is enrolling pediatric patients in need of mitral valve replacement who cannot be implanted with the current range of approved valves without additional risks and who have no alternative approved treatment options.

The HALO IDE trial stems from a new approach to the design, evaluation and regulatory approval of pediatric heart valves that emerged from a FDA-led workshop in 2010 organized in response to the pressing need to develop products for this patient population.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init